

Institutional Biosafety Committee
January 19, 2006
Minutes

Present: Drs. Wetmur, Calfee, Miller, Moline, Wieder (by telephone); Mr. Hauck; Mss. Erlitz, Strauss, and Sadock

- 1) **Approval of Minutes** -- Upon motion duly made and seconded, the minutes of the October 20, 2005 were approved.
- 2) **Review and Approval of Protocols**
 - a. Mr. Hauck will provide the committee with a list of protocols for approval, including specifics of vectors and inserts, and will segregate animal from human protocols.
- 3) **InfoEd**
 - a. Dr. Wetmur and Mr. Hauck working InfoEd to incorporate biosafety directly into the grant submission process.
 - b. Current paper protocols will be approved at the April 27 meeting; after that this Committee will work through InfoEd.
- 4) **Emerging Pathogens Facility**
 - a. Finish work is underway.
 - b. CDC inspection is expected in March.
 - c. IBC will require PDF copies of protocols one month before the quarterly meeting.
 - d. IBC must approve SOPs for the unit because this group reports to the NIH.
- 5) **Protocol Reviews: Attached**
- 6) **GCO#02-1247 (Palese)**
 - a. The committee noted that "SA&T" should be removed from the description because the agent used in this study does not qualify.
 - b. These well-known agents have not demonstrated transmission of disease from animals to humans.
 - c. BSL 2 is sufficient because this virus is the vaccine virus and is safe for humans.
 - d. Approved at BSL 2.
- 7) **Adjournment** -- The meeting adjourned at 4:00 p.m.

**Institutional Biosafety Committee
Protocols Approved January 19, 2006**

Gene Inserts	GCO Number	BSO Rev	Level	GCO Status	IBC Status
Herpes Simplex Vectors in Animals					
HSV virus -SWE695; - wtPS1	04-0041	10/3/2005	BSL-1	Active	approved
Herpes simplex1, 2 Non-vector use	01-0670	8/16/2005	BSL-2	Active	approved
Adeno- Associated Virus in Animals					
AAV type,1,2 ; FIX insertexpressed	04-0786	9/28/2005	BSL-1	Active	approved
rAAV VectorsHuman Alkaline Phosphatase	02-0153	7/6/2005	BSL-2	Active	approved
rAAV Vectors+Musphenylalanine hydroxylase	02-0153	7/6/2005	BSL-2	Active	approved
AAV gene integration into Mus ES cells	03-0556	9/6/2005	BSL-1	Active	approved
AdenoVirus in Animals					
Adenovirus; AdV-VEGF Construct	05-0818	9/8/2005	BSL-2	Pending	approved
AdV vector-Gene Coding for CHIP (protein)	05-0695	8/1/2005	BSL-2	Pending	hold*
Adenovirus Vectors Ad-HTSHR	04-0129	8/1/2005	BSL-2	Pending	approved
Adv-dose study in Human Cancer cells (GT)	03-0597	8/2/2005	BSL-2	Active	approved
AdV, retrovirus vectors FoxP3 into CD4+CD25	00-0479	7/8/2004	BSL-2	Active	approved
Vesicular Stomatitis Virus in Animals					
rVSV-LacZ ,II-12, II-2, GMCSF, HSP70	03-1083	10/3/2005	BSL-2	Pending	Approved**
rVSV vectors ; Beta Galactosidase genes	05-1034	10/3/2005	BSL-2	Pending	approved
VSV-studies; VP22-TK fusion gene	02-0520	6/13/2005	BSL-2	Active	approved
Lentivirus/Retrovirus vectors in Animals					
Lentiviral Vector;-EGFP and siRNA (Not Spec)	05-0982	9/21/2005	BSL-2	Active	approved
MMLV-Retroviral vect; shRNA against TGF-b2	04-0564	4/19/2005	BSL-2	Pending	approved
Lentiviral Vectors si RNA inserts for OligoNu	01-0646	9/30/2004	BSL-2	Active	approved

Gene Inserts	GCO Number	BSO Rev	Level	GCO Status	IBC Status
Influenza vectors in Animals					
Tumor Inoculation PR8					
Influenza Virus; CMS5 Cells	04-0044	9/30/2005	BSL-2	Pending	approved
Influenza (modified for mice)					
dose study	03-0058(2)	5/18/2005	BSL-1	Active	approved
Newcastle Disease virus vectors in Animals					
NewcastleVirus; BaPA and EBOV	02-1247	6/8/2005	BSL-2	Active	approved

*Pending follow-up by BSO

**BSO to notify PI that virus must be rendered less pathogenic.